Addex reports q1 2023 financial results and provides corporate update

Adx71149 phase 2 e pilepsy c linical s tudy's i ndependent i nterim r eview c ommittee (“irc”) r ecommends c ontinuing s tudy  chf 5.6m ($ 6.1 m) of cash and cash equivalents at march 31, 202 3 ad hoc announcement pursuant to art. 53 lr geneva, switzerland, may 11 , 202 3 - addex therapeutics (six: adxn and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the first quarter ended march 31, 2023, and provided a corporate update.
ADXN Ratings Summary
ADXN Quant Ranking